PT-141 Mechanism of Action

PT-141 Overview & Molecular Profile

MECHANISM OF ACTION

PT-141 is a cyclic synthetic peptide and MC3R/MC4R agonist derived from Melanotan II by removing a carboxyl group to eliminate blood-pressure-elevating effects. FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, it is one of very few research peptides to achieve FDA approval. Its mechanism is centrally mediated via hypothalamic and limbic MC4R activation, distinct from PDE5 inhibitors like sildenafil that act peripherally on vascular smooth muscle.

Mechanism of Action: Receptor Agonism & Metabolic Pathways

MOLECULAR STRUCTURE

PT-141 acts as an agonist at melanocortin receptors, particularly MC3R and MC4R, in the central nervous system. These receptors are involved in sexual function and arousal. By activating these pathways, PT-141 affects sexual response through central mechanisms rather than peripheral vascular effects.

From Injection to Effect: The 2.7-Hour Peptide With 24-Hour Activity

PT-141's pharmacokinetic profile presents a striking disconnect between plasma half-life and duration of effect — a pattern seen in several neuroactive peptides where rapid receptor engagement triggers downstream signaling cascades that outlast the peptide's systemic presence.

Melanocortin Pathway Activation

Research demonstrates PT-141's potent agonist activity at melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors, which are critical G-protein coupled receptors involved in regulating sexual behavior, energy homeostasis, and autonomic nervous system function. Binding studies show PT-141 has high affinity for MC4R with EC50 values in the nanomolar range, triggering intracellular signaling cascades that activate cyclic AMP and protein kinase A pathways in hypothalamic neurons. The peptide's cyclic structure, derived from its parent compound Melanotan II, provides enhanced metabolic stability and receptor selectivity compared to linear melanocortin analogs. Research into melanocortin receptor agonist mechanisms has revealed that MC4R activation in the paraventricular nucleus directly influences sexual arousal pathways independent of peripheral hormonal changes. These melanocortin pathway studies have significant implications for understanding central regulation of sexual function, appetite control mechanisms, and potential therapeutic targets for metabolic and reproductive disorders.

FDA-Approved Prescribing Information

PT-141 is an FDA-approved medication. Official prescribing information is available via the NIH National Library of Medicine DailyMed database: